BetaFIT Study: Beta Cell Imaging After Faecal mIcrobiota Transplantation
NCT05622123 on ClinicalTrials.gov · last registry update 2023-04-04
A small phase 2 — 20 participants, against a typical 110. Its estimated completion date, 28 February 2024, has passed with no update to the record. Primary outcome, as filed: Correlation between residual beta cell mass and function. A lapsed estimate is not a result and not a failure — sponsors are slow to refile — but ClinicalTrials.gov marks it nowhere on the record, so it is noted here. exenatide is approved in the US, but not for type 1 diabetes — a registration here is not an approval, and most drugs tested in a new condition never get one for it.
- Status
- UNKNOWN
- Phase
- P2
- Drug
- exenatideBydureon, Byetta
- Sponsor
- Radboud University Medical Center
- Sponsor type
- Other
- Enrollment
- 20
- Started
- 2023-02-23
- Primary completion
- 2024-02-28 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Correlation between residual beta cell mass and function
Conditions studied
Type 1 Diabetes
Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.